GET DAILY SIGNALSJohnson & Johnson (JNJ) Eyes +10.2% Advance Toward $300
Key Takeaways
- The central target used here is $300, a widely watched psychological round-number milestone discussed publicly, not an analyst consensus figure.
- At a recent close of $272.32, reaching $300 would require a gain of roughly 10.2%, a modest but meaningful move.
- The average sell-side price target sits near $279, only about 2% above the latest close, so the $300 level reflects public discussion rather than the mean of analyst targets.
- Analyst targets span a wide range, from roughly $190–$210 at the low end to a Street-high of $320, reflecting sharp disagreement over valuation.
- Strongest supports include oncology momentum, a robust new-product cycle, and raised 2026 guidance; the biggest risks are a rich valuation and patent-expiration pressure.
- For more detail on Major News, Today's Price Move, a Forecast, and Earnings, explore Tickeron's dedicated pages.
- You can also explore Trending AI Robots to see AI-driven trading ideas across the market.
How the $300 Target Came Into Focus
Because the broad analyst consensus already sits within a few percentage points of the current share price, it does not provide a meaningful upside target. Independent trackers place the mean price target at roughly $279, based on roughly 23 to 26 analysts, with a Street-low near $190–$210 and a Street-high of $320. Even averaging only the targets above the latest close leaves a figure below a 10% threshold. Accordingly, this analysis uses $300 as a publicly discussed milestone rather than an analyst consensus: it is a round-number level where several firms have placed targets, and it sits just above the broader average while still below the highest calls from UBS and HSBC at $320. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The shares closed at $272.32 on Nov. 5, 2026, with a market capitalization near $655 billion and a trailing price-to-earnings ratio of roughly 40. The stock has climbed about 33% year to date and roughly 47% over the trailing 12 months, trading within striking distance of a 52-week high near $282. Reaching $300 would require an approximate 10.2% advance — a modest move that the stock has demonstrated it can generate in short bursts, but one that now hinges on valuation willingness rather than simply on business momentum.
What Could Support a Move Toward the Target
Johnson & Johnson (JNJ)'s oncology franchise is the clearest driver, led by Darzalex and Carvykti, with several analysts projecting substantial multi-year sales growth. Immunology assets such as Tremfya and newer pipeline medicines are expected to help offset erosion in Stelara, which faces loss of exclusivity. MedTech is also contributing, with positive Impella heart-pump data and an electrophysiology business showing double-digit growth. Management has raised fiscal 2026 guidance, now expecting adjusted EPS of $11.05 to $11.15 on revenue of $101 billion to $101.4 billion, and the company pays a dividend yielding about 1.9%.
What Could Prevent the Target From Being Reached
The principal obstacle is valuation. At a trailing P/E near 40, the stock trades well above its own long-term history and above the broader pharmaceutical peer group, leaving little room for disappointment. Third-quarter 2026 revenue of roughly $25.4 billion fell short of consensus even as adjusted EPS beat estimates, a reminder that elevated expectations cut both ways. Stelara's patent expiration remains a structural drag, talc and product-liability litigation persists, and competition across oncology, immunology, and MedTech is intensifying. A rotation away from large-cap healthcare or rising interest rates could also compress the multiple.
Technical Levels and Market Structure
The shares are consolidating just below the 52-week high near $282, which now acts as the nearest resistance level. A decisive break above that area would open the path toward the psychologically significant $300 zone. On the downside, the stock's prior consolidation area near $258–$260 and the rising 20-day and 60-day moving averages provide nearby support levels, with a deeper floor near the low-$240s. The long-term trend structure remains firmly bullish, but the proximity to recent highs leaves limited historical reference points above current levels. From what I see, these levels are worth monitoring closely in the weeks ahead.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different frameworks. Investors should watch the next quarterly earnings report, guidance updates, and any analyst target revisions around results, as well as oncology readouts, Impella and MedTech data, and developments in the planned orthopaedics separation and ongoing litigation. Changes in the FOMC's rate path and sector fund flows can also influence how richly the market is willing to value defensive healthcare names.
AI Daily Buy/Sell Signals
In my own workflow, Tickeron's AI Daily Buy/Sell Signals provide a useful layer when reviewing names like this. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors tracking a name like JNJ, such tools can add a data-driven layer to fundamental research.
Final Assessment
Whether JNJ reaches $300 depends less on the company's operating trajectory — which remains constructive — than on whether investors are willing to pay an even higher multiple. The required 10.2% move is modest in absolute terms, and the oncology-led product cycle, raised guidance, and MedTech momentum provide genuine support. Against that stand a demanding valuation, patent-expiration pressure, and a sell-side consensus that already sits just above the current price, with targets spanning from near $190 to $320. Investors should weigh the strength of the fundamentals against the market's willingness to keep rewarding the shares at these levels. In my view, the setup remains balanced but valuation-sensitive.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
JNJ's RSI Indicator recovers from oversold territory
The RSI Indicator for JNJ moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 18 of the 30 cases the stock moved higher. This puts the odds of a move higher at 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 20 of 47 cases over the following month. The odds of a continued upward trend are 43%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 41%.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.723) is normal, around the industry mean (-1.288). P/E Ratio (31.194) is within average values for comparable stocks, (21.647). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement